FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2074869345> ?p ?o ?g. }

• W2074869345 endingPage "S11" @default.
• W2074869345 startingPage "S2" @default.
• W2074869345 abstract "Doxazosin is the latest in a series of highly selective postsynaptic alpha 1-adrenoceptor inhibitors. It is readily absorbed, with high bioavailability and a relatively long plasma half-life, neither of which property is influenced by age. This accounts for the prolonged pharmacologic activity of doxazosin following a single oral dose. Its prime pharmacodynamic activity resides in its ability to counter sympathetic vasoconstriction of the systemic arteriolar resistance vessels and venous capacitance system, which enables the drug to target the major pathophysiologic abnormality in hypertension, i.e., the generalized systemic arteriolar constriction. The widespread vasodilation induced by doxazosin relieves both cardiac preload and afterload and, consequently, reduces left ventricular wall stress and myocardial oxygen consumption. In hypertension, doxazosin reduces blood pressure both at rest and during exercise by reduction of systemic vascular resistance without precipitating substantial reflex cardiac stimulation. The effects are maximal on the standing blood pressure between two and four hours after ingestion; due to doxazosin's relatively slow absorption, postural hypotension is infrequent. Its antihypertensive activity is maintained over 24 hours following a single oral dose, and the optimal dose range is 2 to 8 mg once daily. The antihypertensive efficacy of doxazosin has been shown to be comparable with that of other alpha-adrenoceptor inhibitors, beta-blocking drugs, diuretics, calcium antagonists, and angiotensin-converting enzyme inhibitors. In contrast to other conventional antihypertensive drugs, a unique feature of alpha-adrenoceptor-inhibiting drugs, including doxazosin, is their ability to reduce the plasma concentrations of triglycerides, total cholesterol, and low-density lipoprotein cholesterol and to increase high-density lipoprotein cholesterol concentration. This contrasts with the opposite effect on lipid levels induced by hydrochlorothiazide and atenolol seen in comparative studies. Side effects show no predilection for any organ system, and the overall incidence of such effects compares well with those of other commonly used antihypertensive drugs. This unique combination of antihypertensive efficacy and favorable effect on blood lipid levels indicates that once-daily treatment with doxazosin holds considerable promise in the treatment of hypertension, both from the point of view of its antihypertensive efficacy and also from its primary preventative potential." @default.
• W2074869345 created "2016-06-24" @default.
• W2074869345 creator A5063136194 @default.
• W2074869345 date "1989-08-01" @default.
• W2074869345 modified "2023-09-24" @default.
• W2074869345 title "Clinical Pharmacotherapeutics of Doxazosin" @default.
• W2074869345 cites W1563600411 @default.
• W2074869345 cites W1954463628 @default.
• W2074869345 cites W1963657067 @default.
• W2074869345 cites W1963903183 @default.
• W2074869345 cites W1967985447 @default.
• W2074869345 cites W1970194195 @default.
• W2074869345 cites W1981871828 @default.
• W2074869345 cites W1985273761 @default.
• W2074869345 cites W1987060049 @default.
• W2074869345 cites W1990649996 @default.
• W2074869345 cites W1990854157 @default.
• W2074869345 cites W1993658009 @default.
• W2074869345 cites W1999377124 @default.
• W2074869345 cites W1999692915 @default.
• W2074869345 cites W2005412936 @default.
• W2074869345 cites W2006450095 @default.
• W2074869345 cites W2012673034 @default.
• W2074869345 cites W2015008192 @default.
• W2074869345 cites W2015609864 @default.
• W2074869345 cites W2019024294 @default.
• W2074869345 cites W2019030153 @default.
• W2074869345 cites W2020033113 @default.
• W2074869345 cites W2021922903 @default.
• W2074869345 cites W2022770616 @default.
• W2074869345 cites W2025205636 @default.
• W2074869345 cites W2028457127 @default.
• W2074869345 cites W2030717669 @default.
• W2074869345 cites W2030970399 @default.
• W2074869345 cites W2037776386 @default.
• W2074869345 cites W2039935433 @default.
• W2074869345 cites W2040566654 @default.
• W2074869345 cites W2046081581 @default.
• W2074869345 cites W2049460546 @default.
• W2074869345 cites W2049943934 @default.
• W2074869345 cites W2054101393 @default.
• W2074869345 cites W2057594935 @default.
• W2074869345 cites W2060506112 @default.
• W2074869345 cites W2068759643 @default.
• W2074869345 cites W2072389943 @default.
• W2074869345 cites W2072700274 @default.
• W2074869345 cites W2074773151 @default.
• W2074869345 cites W2077029614 @default.
• W2074869345 cites W2079253221 @default.
• W2074869345 cites W2081634133 @default.
• W2074869345 cites W2122205845 @default.
• W2074869345 cites W2133142353 @default.
• W2074869345 cites W2143336465 @default.
• W2074869345 cites W2152551266 @default.
• W2074869345 cites W2238525991 @default.
• W2074869345 doi "https://doi.org/10.1016/0002-9343(89)90107-1" @default.
• W2074869345 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2569822" @default.
• W2074869345 hasPublicationYear "1989" @default.
• W2074869345 type Work @default.
• W2074869345 sameAs 2074869345 @default.
• W2074869345 citedByCount "17" @default.
• W2074869345 countsByYear W20748693452018 @default.
• W2074869345 countsByYear W20748693452019 @default.
• W2074869345 countsByYear W20748693452021 @default.
• W2074869345 crossrefType "journal-article" @default.
• W2074869345 hasAuthorship W2074869345A5063136194 @default.
• W2074869345 hasConcept C120770815 @default.
• W2074869345 hasConcept C126322002 @default.
• W2074869345 hasConcept C134018914 @default.
• W2074869345 hasConcept C2777590997 @default.
• W2074869345 hasConcept C2779961880 @default.
• W2074869345 hasConcept C58245268 @default.
• W2074869345 hasConcept C71924100 @default.
• W2074869345 hasConcept C84393581 @default.
• W2074869345 hasConcept C98274493 @default.
• W2074869345 hasConceptScore W2074869345C120770815 @default.
• W2074869345 hasConceptScore W2074869345C126322002 @default.
• W2074869345 hasConceptScore W2074869345C134018914 @default.
• W2074869345 hasConceptScore W2074869345C2777590997 @default.
• W2074869345 hasConceptScore W2074869345C2779961880 @default.
• W2074869345 hasConceptScore W2074869345C58245268 @default.
• W2074869345 hasConceptScore W2074869345C71924100 @default.
• W2074869345 hasConceptScore W2074869345C84393581 @default.
• W2074869345 hasConceptScore W2074869345C98274493 @default.
• W2074869345 hasIssue "2" @default.
• W2074869345 hasLocation W20748693451 @default.
• W2074869345 hasLocation W20748693452 @default.
• W2074869345 hasOpenAccess W2074869345 @default.
• W2074869345 hasPrimaryLocation W20748693451 @default.
• W2074869345 hasRelatedWork W1591297981 @default.
• W2074869345 hasRelatedWork W1966234050 @default.
• W2074869345 hasRelatedWork W1991115983 @default.
• W2074869345 hasRelatedWork W2020128704 @default.
• W2074869345 hasRelatedWork W2152963652 @default.
• W2074869345 hasRelatedWork W2171089442 @default.
• W2074869345 hasRelatedWork W2367349695 @default.
• W2074869345 hasRelatedWork W3123591071 @default.
• W2074869345 hasRelatedWork W60828312 @default.

• next